Compare Amphastar Pharmaceuticals Inc (AMPH) vs Kraft Heinz Co (KHC) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Kraft Heinz (KHC) trades at $24.85, up 0.69% with bullish technical momentum including a golden cross formation. The company shows mixed fundamentals with strong cash flow generation ($4.46B operating cash flow in 2025) but negative profitability metrics (-23.05% net margin). Recent earnings beats and a 6.4% dividend yield provide support, while the company's global reorganization aims to accelerate growth. Technical indicators show bullish moving averages with neutral oscillators, trading near key resistance at $25.

KHC presents a value opportunity with attractive valuation (P/E 13.04, P/B 0.7) and high dividend yield, but faces significant profitability challenges. The stock's upside depends on successful execution of restructuring initiatives and margin improvement. Key risks include persistent negative earnings, competitive pressures, and execution missteps in the new operating structure. Analyst consensus remains cautious with only 11% buy ratings despite recent positive technical momentum.